Showing results (291-300 of 386) with videos related to
Sort By:
Pageof 39
Virchows Archiv : an International Journal of Pathology|July 3, 2019
ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literatureStefano La Rosa, Marco Volante, Silvia Uccella, et al.The American Journal of Surgical Pathology|December 29, 2023
Diagnostic Utility of a Modified Reticulin Algorithm in Pediatric Adrenocortical NeoplasmsOscar Lopez-Nunez, Calogero Virgone, Irina S Kletskaya, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance schemeAntonio Marchetti, Massimo Barberis, Mauro Papotti, et al.International Journal of Molecular Sciences|January 26, 2020
<i>NTRK</i> Fusions in Central Nervous System Tumors: A Rare, but Worthy TargetAlessandro Gambella, Rebecca Senetta, Giammarco Collemi, et al.BMC Cancer|November 6, 2009
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology networkMaria P Brizzi, Alfredo Berruti, Anna Ferrero, et al.Oncotarget|February 18, 2016
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancerMarco Lo Iacono, Consuelo Buttigliero, Valentina Monica, et al.European Journal of Endocrinology|December 23, 2011
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinomaAlfredo Berruti, Paola Sperone, Anna Ferrero, et al.Neuroendocrinology|January 26, 2017
The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated ParagangliomasLindsey Oudijk, Thomas Papathomas, Ronald de Krijger, et al.Virchows Archiv : an International Journal of Pathology|February 2, 2018
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigmGiuseppe Pelosi, Fabrizio Bianchi, Elisa Dama, et al.Cancer Letters|February 22, 2019
Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphataseIacopo Gesmundo, Laura Di Blasio, Dana Banfi, et al.Pageof 39